Cargando…
Secondary effects after belantamab treatment: A new anti‐B‐cell maturation antigen monoclonal antibody for multiple myeloma
Autores principales: | Garrido Paniagua, Sara, Prieto Martínez, Pablo, Cachón, Rafael Forés, Bautista Carrascosa, Guiomar, Duarte, Rafael F., Krsnik, Isabel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176025/ https://www.ncbi.nlm.nih.gov/pubmed/35844696 http://dx.doi.org/10.1002/jha2.205 |
Ejemplares similares
-
A rare case of relapsed multiple myeloma with aberrant T‐cell antigen expression and skin plasmacytomas
por: Lecat, Catherine S.Y., et al.
Publicado: (2021) -
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
por: Shragai, Tamir, et al.
Publicado: (2022) -
Lymphoplasmacytic variant of multiple myeloma
por: Johansen, Silje, et al.
Publicado: (2022) -
Myeloma‐induced leucocytoclastic vasculitis
por: De Abrew, Kanchana, et al.
Publicado: (2020) -
Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)